Tgfbr2 Ko Car27/Il-15 Nk Cells
Lymphoid System Disorder
Explore 4 assets in Lymphoid System Disorder →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07444632CT.gov Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoid System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tgfbr2 Ko Car27/Il-15 Nk Cells (this asset) | M.D. Anderson Cancer Center | P1 | CC · 43 |
| Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) | Geron Corporation | P1 | CC |
| il-15 enhanced engineered nk cells | M.D. Anderson Cancer Center | P1 | CC |
| Cyclophosphamide | M.D. Anderson Cancer Center | P1 | CC |
| Fludarabine | M.D. Anderson Cancer Center | P1 | CC |
Other indications for Tgfbr2 Ko Car27/Il-15 Nk Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neoplasm | — | P1/2 | CC · 40 |
| Hodgkins Lymphoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)Geron CorporationCC
- il-15 enhanced engineered nk cellsM.D. Anderson Cancer CenterCC
- CyclophosphamideM.D. Anderson Cancer CenterCC
- FludarabineM.D. Anderson Cancer CenterCC
Citation
Floatz Terminal. Tgfbr2 Ko Car27/Il-15 Nk Cells in Lymphoid System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tgfbr2-ko-car27il-15-nk-cells-lymphoid-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →